Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Insulin→

Insulin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
9004-10-8
Molecular formula
C256H381N65O77S6
Molecular weight
5794 g/mol
Drug class
Peptide hormoneantidiabetic agent
Mechanism of action
Activates the insulin receptor tyrosine kinase, promoting peripheral glucose uptake (especially in skeletal muscle and adipose tissue) and inhibiting hepatic glucose production. It also inhibits lipolysis and proteolysis and promotes glycogen, lipid and protein synthesis.
Indications / reported uses
  • Treatment of diabetes mellitus, including type 1 diabetes and type 2 diabetes when insulin therapy is required.
  • Management of hyperglycaemia in selected acute-care settings with appropriate intravenous insulin formulations.

Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b519bd83-038c-4ec5-a231-a51ec5cc291f · https://www.ncbi.nlm.nih.gov/books/NBK545190/

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Insulin Environmental Risk Assessment (ERA) (the Insulin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.